Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study to Evaluate Cefepime-taniborbactam Compared to Meropenem in Adults with Ventilator Associated Bacterial Pneumonia (VABP) or Ventilated Hospital Acquired Bacterial Pneumonia (vHABP)

Next Previous
Trial Profile

A Phase 3 Study to Evaluate Cefepime-taniborbactam Compared to Meropenem in Adults with Ventilator Associated Bacterial Pneumonia (VABP) or Ventilated Hospital Acquired Bacterial Pneumonia (vHABP)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cefepime/taniborbactam (Primary) ; Meropenem
  • Indications Nosocomial pneumonia; Ventilator associated pneumonia
  • Focus Therapeutic Use
  • Acronyms CERTAIN-2
  • Sponsors VenatoRx Pharmaceuticals

Most Recent Events

  • 25 Mar 2025 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 30 Oct 2024 Planned End Date changed from 1 Sep 2027 to 1 Dec 2027.
  • 30 Oct 2024 Planned primary completion date changed from 1 Mar 2027 to 1 Jun 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top